dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Oertel, Frederike Cosima |
dc.contributor.author | Specovius, Svenja |
dc.contributor.author | Zimmermann, Hanna G |
dc.contributor.author | Chien, Claudia |
dc.contributor.author | Motamedi, Seyedamirhosein |
dc.contributor.author | Bereuter, Charlotte |
dc.contributor.author | Cobo Calvo, Alvaro |
dc.date.accessioned | 2022-05-12T08:25:48Z |
dc.date.available | 2022-05-12T08:25:48Z |
dc.date.issued | 2021-11 |
dc.identifier.citation | Oertel FC, Specovius S, Zimmermann HG, Chien C, Motamedi S, Bereuter C, et al. Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter study. Neurol Neuroimmunol Neuroinflamm. 2021 Nov;8(6):e1068. |
dc.identifier.issn | 2332-7812 |
dc.identifier.uri | https://hdl.handle.net/11351/7513 |
dc.description | Retina; Visual loss |
dc.description.abstract | Background and Objectives To determine optic nerve and retinal damage in aquaporin-4 antibody (AQP4-IgG)-seropositive neuromyelitis optica spectrum disorders (NMOSD) in a large international cohort after previous studies have been limited by small and heterogeneous cohorts.
Methods The cross-sectional Collaborative Retrospective Study on retinal optical coherence tomography (OCT) in neuromyelitis optica collected retrospective data from 22 centers. Of 653 screened participants, we included 283 AQP4-IgG–seropositive patients with NMOSD and 72 healthy controls (HCs). Participants underwent OCT with central reading including quality control and intraretinal segmentation. The primary outcome was thickness of combined ganglion cell and inner plexiform (GCIP) layer; secondary outcomes were thickness of peripapillary retinal nerve fiber layer (pRNFL) and visual acuity (VA).
Results Eyes with ON (NMOSD-ON, N = 260) or without ON (NMOSD-NON, N = 241) were assessed compared with HCs (N = 136). In NMOSD-ON, GCIP layer (57.4 ± 12.2 μm) was reduced compared with HC (GCIP layer: 81.4 ± 5.7 μm, p < 0.001). GCIP layer loss (−22.7 μm) after the first ON was higher than after the next (−3.5 μm) and subsequent episodes. pRNFL observations were similar. NMOSD-NON exhibited reduced GCIP layer but not pRNFL compared with HC. VA was greatly reduced in NMOSD-ON compared with HC eyes, but did not differ between NMOSD-NON and HC.
Discussion Our results emphasize that attack prevention is key to avoid severe neuroaxonal damage and vision loss caused by ON in NMOSD. Therapies ameliorating attack-related damage, especially during a first attack, are an unmet clinical need. Mild signs of neuroaxonal changes without apparent vision loss in ON-unaffected eyes might be solely due to contralateral ON attacks and do not suggest clinically relevant progression but need further investigation. |
dc.language.iso | eng |
dc.publisher | Wolters Kluwer Health |
dc.relation.ispartofseries | Neurology - Neuroimmunology & Neuroinflammation;8(6) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Trastorns de la visió - Imatgeria |
dc.subject | Sistema nerviós - Malalties |
dc.subject | Ulls - Tomografia |
dc.subject.mesh | Neuromyelitis Optica |
dc.subject.mesh | /diagnostic imaging |
dc.subject.mesh | Tomography, Optical Coherence |
dc.title | Retinal Optical Coherence Tomography in Neuromyelitis Optica |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1212/NXI.0000000000001068 |
dc.subject.decs | neuromielitis óptica |
dc.subject.decs | /diagnóstico por imagen |
dc.subject.decs | tomografía de coherencia óptica |
dc.relation.publishversion | https://doi.org/10.1212/NXI.0000000000001068 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Oertel FC] Experimental and Clinical Research Center, Max Delbruck Center for Molecular Medicine and Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany. NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Germany. Department of Neurology, University of California San Francisco, CA. [Specovius S, Zimmermann HG, Chien C, Motamedi S, Bereuter C] Experimental and Clinical Research Center, Max Delbruck Center for Molecular Medicine and Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany. NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Germany. [Cobo-Calvo A] Biomedical Center and University Hospital, Ludwig-Maximilians Universitaet Muenchen, Munich, Germany. Neurology, Multiple Sclerosis, Myelin Disorders and Neuroinflammation, Pierre Wertheimer Neurological Hospital, Hospices Civils de Lyon, France. Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Servei de Neurologia-Neuroimmunologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 34526385 |
dc.identifier.wos | 000712132000033 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |